Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Solventum Corporation (SOLV) and Shattuck Labs (STTK)

Tipranks - Tipranks - Tue Apr 14, 6:50AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dexcom (DXCM), Solventum Corporation (SOLV) and Shattuck Labs (STTK) with bullish sentiments.

Claim 30% Off TipRanks

Dexcom (DXCM)

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Dexcom, with a price target of $80.00. The company’s shares closed last Friday at $64.02, close to its 52-week low of $62.34.

According to TipRanks.com, Thibault is ranked 0 out of 5 stars with an average return of -14.5% and a 31.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Orchestra BioMed Holdings, and Edwards Lifesciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $86.50 average price target, which is a 31.3% upside from current levels. In a report issued on April 2, TD Cowen also maintained a Buy rating on the stock with a $84.00 price target.

See today’s best-performing stocks on TipRanks >>

Solventum Corporation (SOLV)

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Solventum Corporation, with a price target of $89.00. The company’s shares closed last Friday at $65.79.

According to TipRanks.com, Zimmerman is a 1-star analyst with an average return of -0.4% and a 40.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Shoulder Innovations, Inc., and Tactile Systems Technology. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Solventum Corporation with a $90.40 average price target, which is a 36.4% upside from current levels. In a report issued on April 6, J.P. Morgan also initiated coverage with a Buy rating on the stock.

Shattuck Labs (STTK)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Shattuck Labs, with a price target of $15.00. The company’s shares closed last Friday at $6.92.

According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 27.4% and a 45.2% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Praxis Precision Medicines, and Crinetics Pharmaceuticals. ;'>

Shattuck Labs has an analyst consensus of Strong Buy, with a price target consensus of $10.00.

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).